BALTIMORE, Sept. 11, 2024 ~ In a recent press release, Previse, a company specializing in gastrointestinal health, announced the publication of a study in Diagnostics showcasing the analytical validation of their groundbreaking DNA methylation test, Esopredict. This test is designed to identify patients with precancerous Barrett's esophagus (BE) who are at risk of developing high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in the future.

According to Sarah Laun, PhD and Vice President of Research and Development at Previse, this new study serves as a complement to Esopredict's previously published clinical validation study. Laun stated that the results of this analytical validation demonstrate the strong performance of the Esopredict assay, which is conducted in Previse's CLIA laboratory located in Baltimore.

More on Marylandian

• Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
• OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
• Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
• Heritage at South Brunswick's Townhome Models Coming Soon!
• PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth

The publication, titled "Analytical Validation of Esopredict: An Epigenetic Prognostic Assay for Patients with Barrett's Esophagus," provides rigorous confirmation of the robustness and reproducibility of Esopredict. The data also showcases the high precision and reproducibility of the assay across various levels of risk. This further solidifies Esopredict as a reliable tool for identifying patients at risk for developing BE-related cancers.

---

Show All News | Report Violation